Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All vitamin D studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchVitamin DVitamin D (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Case 42% Improvement Relative Risk Vitamin D for COVID-19  Fasano et al.  Prophylaxis Does vitamin D reduce COVID-19 infections? Retrospective 1,486 patients in Italy Fewer cases with vitamin D (p=0.048) c19early.org Fasano et al., Movement Disorders, Jun 2021 Favors vitamin D Favors control

COVID-19 in Parkinson’s Disease Patients Living in Lombardy, Italy

Fasano et al., Movement Disorders, doi:10.1002/mds.28176
Jun 2021  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Vitamin D for COVID-19
8th treatment shown to reduce risk in October 2020
 
*, now known with p < 0.00000000001 from 119 studies, recognized in 7 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,900+ studies for 60+ treatments. c19early.org
Retrospective phone survey of 1,486 Parkinson's disease patients in Italy, showing lower risk of COVID-19 cases with vitamin D supplementation. This paper also presents a case control study of PD patients and family member control patients.
This is the 39th of 119 COVID-19 controlled studies for vitamin D, which collectively show efficacy with p<0.0000000001 (1 in 116 sextillion). 29 studies are RCTs, which show efficacy with p=0.0000035.
risk of case, 42.0% lower, RR 0.58, p = 0.048, treatment 13 of 329 (4.0%), control 92 of 1,157 (8.0%), NNT 25, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Fasano et al., 2 Jun 2021, retrospective, Italy, peer-reviewed, 7 authors, dosage not specified.
This PaperVitamin DAll
COVID‐19 in Parkinson’s Disease Patients Living in Lombardy, Italy
MD Alfonso Fasano, MD Emanuele Cereda, MD Michela Barichella, MD Erica Cassani, MD Valentina Ferri, MD Anna Lena Zecchinelli, MD Gianni Pezzoli
Movement Disorders, doi:10.1002/mds.28176
Background: It is unknown whether patients with PD are at greater risk of COVID-19, what their risk factors are, and whether their clinical manifestations differ from the general population. Objectives: The study aimed to address all these issues. Methods: In a case-controlled survey, we interviewed 1,486 PD patients attending a single tertiary center in Lombardy, Italy and 1,207 family members (controls). Results: One hundred five (7.1%) and 92 controls (7.6%) were identified as COVID-19 cases. COVID-19 patients were younger, more likely to suffer from chronic obstructive pulmonary disease, to be obese, and vitamin D nonsupplemented than unaffected patients. Six patients (5.7%) and 7 family members (7.6%) died from COVID-19. Patients were less likely to report shortness of breath and require hospitalization. Conclusions: In an unselected large cohort of nonadvanced PD patients, COVID-19 risk and mortality did not differ from the general population, but symptoms appeared to be milder. The possible protective role of vitamin D supplementation warrants future studies.
Supporting Data Additional Supporting Information may be found in the online version of this article at the publisher's web-site.
References
Antonini, Leta, Teo, Chaudhuri, Outcome of Parkinson's disease patients affected by COVID-19, Mov Disord, doi:10.1002/mds.28104
Baille, Chenivesse, Perez, Dyspnea: an underestimated symptom in Parkinson's disease, Parkinsonism Relat Disord
Baille, Jesus, Perez, Ventilatory dysfunction in Parkinson's disease, J Parkinsons Dis
Carter, Baranauskas, Fly, Considerations for obesity, vitamin D, and physical activity amidst the COVID-19 pandemic, Obesity, doi:10.1002/oby.22838
D'avolio, Avataneo, Manca, 25-Hydroxyvitamin D concentrations are lower in patients with positive PCR for SARS-CoV-2, Nutrients
Ddp, COVID-19 Italia-Monitoraggio della situazione
Fasano, Antonini, Katzenschlager, Management of advanced therapies in Parkinson's disease patients in times of humanitarian crisis: the COVID-19 experience, Mov Disord Clin Pract
Fasano, Elia, Dallocchio, Predictors of COVID-19 outcome in Parkinson's disease
Filatov, Sharma, Hindi, Espinosa, Neurological complications of coronavirus disease (COVID-19): encephalopathy, Cureus
Gardner, States, Bagley, The coronavirus and the risks to the elderly in long-term care, J Aging Soc Policy, doi:10.1080/08959420.2020.1750543
Gordon, Jang, Bouhaddou, A SARS-CoV-2-human protein-protein interaction map reveals drug targets and potential drug-repurposing, bioRxiv, doi:10.1101/2020.03.22.002386
Grant, Lahore, Mcdonnell, Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths, Nutrients
Grasselli, Zangrillo, Zanella, Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy, JAMA
Helmich, Bloem, The impact of the COVID-19 pandemic on Parkinson's disease: hidden sorrows and emerging opportunities, J Parkinsons Dis
Huang, Wang, Li, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Ilie, Stefanescu, Smith, The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality, Aging Clin Exp Res, doi:10.1007/s40520-020-01570-8
Jakovac, COVID-19 and vitamin D-Is there a link and an opportunity for intervention?, Am J Physiol Endocrinol Metab
Jarcho, Ingelfinger, Hamel, Agostino, Harrington, Inhibitors of the renin-angiotensin-aldosterone system and Covid-19, N Engl J Med, doi:10.1056/NEJMe2012924
Jayawardena, Sooriyaarachchi, Chourdakis, Jeewandara, Ranasinghe, Enhancing immunity in viral infections, with special emphasis on COVID-19: a review, Diabetes Metab Syndr
Kakodkar, Kaka, Baig, A comprehensive literature review on the clinical presentation, and management of the pandemic coronavirus disease 2019 (COVID-19), Cureus
Kittleson, The invisible hand-medical care during the pandemic, N Engl J Med
Ko, Kang, Lee, Levodopa-induced respiratory dysfunction confirmed by levodopa challenge test: a case report, Medicine
Little, Non-steroidal anti-inflammatory drugs and covid-19, BMJ
Marik, Kory, Varon, Does vitamin D status impact mortality from SARS-CoV-2 infection?, Med Drug Discov, doi:10.1016/j.medidd.2020.100041
Mccartney, Byrne, Optimisation of vitamin D status for enhanced immuno-protection against Covid-19, Ir Med J
Monteiro, Souza-Machado, Valderramas, Melo, The effect of levodopa on pulmonary function in Parkinson's disease: a systematic review and meta-analysis, Clin Ther
Nataf, An alteration of the dopamine synthetic pathway is possibly involved in the pathophysiology of COVID-19, J Med Virol, doi:10.1002/jmv.25826
Onder, Rezza, Brusaferro, Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy, JAMA, doi:10.1001/jama.2020.4683
Papa, Brundin, Fung, Impact of the COVID-19 pandemic on Parkinson's disease and movement disorders, Mov Disord Clin Pract
Postuma, Berg, Stern, MDS clinical diagnostic criteria for Parkinson's disease, Mov Disord
Prasad, Holla, Neeraja, Parkinson's disease and COVID-19: perceptions and implications in patients and caregivers, Mov Disord, doi:10.1002/mds.28088
Silberstein, Vitamin D: a simpler alternative to tocilizumab for trial in COVID-19?, Med Hypotheses
Smieszek, Przychodzen, Polymeropoulos, Amantadine disrupts lysosomal gene expression; potential therapy for COVID19, bioRxiv, doi:10.1101/2020.04.05.026187
Torres, Maheswari, Parthasarathy, Ng, Liu et al., Conductance and amantadine binding of a pore formed by a lysineflanked transmembrane domain of SARS coronavirus envelope protein, Protein Sci
Zheng, Peng, Xu, Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis, J Infect, doi:10.1016/j.jinf.2020.04.021
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit